Urinalysis solutions for Point of Care

Point of Care urinalysis solutions you can trust for both professional and home care settings.


A general practitioner discusses urinalysis Point of Care solutions with a pregnant woman

Your trusted urinalysis solution for Point of Care: Over 60 years of Roche expertise

Fast, reliable, and innovative urinalysis POC

Urinalysis has always been an important diagnostic tool in healthcare. Even today, urine is still a key health barometer for many diseases, including renal disease, urinary tract infections (UTIs), liver disorders, diabetes mellitus, and general hydration. These diseases can cause severe damage if undetected, but urinalysis tests can reveal serious diseases in their early, treatable stages.2,3

With over 60 years of experience, Roche Urinalysis at the Point of Care (POC) now offers a comprehensive solution to support healthcare professionals across diverse settings. This solution combines advanced urine strip technology, a user-friendly urine analyzer, and the seamlessly integrated navify® Integrator digital platform.

Our commitment doesn’t stop there. We continuously develop and refine our solutions to ensure efficiency, safety, and reliability. You can trust Roche Urinalysis for fast, reliable results. This is particularly valuable for decentralized facilities, such as general practitioners, hospitals with decentralized wards, and small laboratories where immediate results can streamline workflows and support quick, informed treatment decisions.4-7

Choose Roche Urinalysis, and leverage our innovation and reliability to transform your diagnostics and patient care.

Featured products

No products found for this filter.

Benefits of urinalysis solutions at the Point of Care from Roche

Take informed decisions with fast and reliable diagnostics

  • Rapid Point of Care testing (POCT) improves UTI management: The value of urinalysis POCT in managing UTIs is widely recognized in primary care.8 Rapid, accurate diagnostics support timely treatment decisions, reduce mismanagement and antibiotic misuse, and minimize unnecessary retesting and visits, leading to improved treatment outcomes and patient satisfaction.8,9
  • Empowering better care through early detection: Roche's urinalysis POC solutions is designed to enable better care. It enables early detection of asymptomatic diseases, supporting healthcare professionals in quickly investigating, diagnosing, and screening for conditions.5
  • The Combur-Test® urinalysis test strips deliver results in just 60 seconds.6 When paired with Roche’s semi-automatic urine analyzer, they enhance diagnostic workflow efficiency and support informed clinical decisions at the Point of Care4,10—all while offering patients a low-risk, low-distress diagnostic option.

Deliver diagnostic excellence across your lab network

  • Consistent accuracy: Potential errors caused by visual comparison and interpretation can raise concerns. We are dedicated to consistent accuracy from diagnosis and screenings to preventive examination. Combur-Test® urinalysis test strips, compatible with Roche analyzers, reduce interference from substances like glue and ascorbic acid. This prevents false negatives for glucose and hemoglobin, ensuring reliable results.6,11-13
  • Advance analytical capacity: Consistent, precise, and accurate results are essential for clinical diagnostics labs.4,5,14 The Urisys® 1100 offers good analytical performance in Urinary Tract Infection (UTI) diagnosis, with results for nitrites, leukocytes, and erythrocytes closely matching lab reference standards.10 Its automated operation minimizes errors, ensuring dependable outcomes.15

Transform efficiency and productivity with smarter management

  • Boost daily operation performance: POC urine analysis is easier to use and interpret than standard culture, enhancing diagnostic efficiency and productivity in general practice.14,15 With ongoing enhancements in usability and flexible connectivity, our urinalysis POCT solutions are dedicated to support your daily operations, empowering you to work smarter and deliver fast, quality results.4
  • Streamlined automation for better care: Experience fast, accurate readings for 10 common urine16 parameters with a Roche test strip.5 Integrate with our digital solution to automate tasks like software updates and patient data management,4 freeing yourself to focus on what truly matters—delivering the best possible care.

Unlock the value of Roche urinalysis POCT for UTIs

  • Cut healthcare cost for the long-term: POCT for UTIs offers positive economic advantages by potentially reducing treatment failures, complications, and hospital admissions, ultimately lowering long-term healthcare costs.9,14,17

    Compared to traditional lab-based methods, POCT alleviates the laboratory burden of urine specimen processing and its associated costs.9 Additionally, POCT enhances antibiotic prescription practices, helping to combat the long-term, expensive treatment expenses related to resistant UTIs.18,19

Contact us

Do you have questions about our products or services? We’re here to help. Contact a Roche representative in your region.

References:

  1.  Wu X. Urinalysis: a review of methods and procedures. Crit Care Nurs Clin North Am. 2010;22(1):121-8.
  2. Krogsbøll LT et al. Screening with urinary dipsticks for reducing morbidity and mortality. Cochrane Database Syst Rev. 2015 28;1(1).
  3. Dolscheid-Pommerich RC et al. Evaluation of the appropriate time period between sampling and analyzing for automated urinalysis. Biochem Med (Zagreb). 2016;26:82-9.
  4. Urisys® 1100 Operator’s Manual version 11.0.
  5. Hoffmann-La Roche Ltd. Combur10 Test® UX, Method Sheet version 8.0.
  6. Hoffmann-La Roche Ltd. Combur 10 Test strip, Method sheet version 4.0.
  7. Hoffmann-La Roche Ltd. Control-Test M, Method Sheet version 4.0.
  8. Brookes-Howell et al. Challenges in managing urinary tract infection and the potential of a point-of-care test guided care in primary care: an international qualitative study. BJGP Open. 2019;3(2).
  9. Horizon Scan Report 0045. Point-of-care testing for urinary tract infections. 2016.
  10. Schot MJ et al. Analytical performance, agreement and user-friendliness of six point-of-care testing urine analysers for urinary tract infection in general practice. BMJ Open. 2015: 5:e006857.
  11.  Iris iChemVELOCITY, FDA 510(k) clearance, K101852 (2011), p.11 and K171083 (2017).
  12. Siemens clinitek novus, FDA 510(K) clearance, K140717, 2014, pp. 16-17.
  13. Arkray Aution AU-4050, FDA 510(K) clearance, K121456, 2013, pp. 22-23.
  14. Tomlinson E et al. Clinical effectiveness of point of care tests for diagnosing urinary tract infection: a systematic review. Clin Microbiol Infect. 2024;30(2):197-205.
  15. van Delft S et al. Prospective, observational study comparing automated and visual point-of-care urinalysis in general practice. BMJ Open. 2016;6(8):e011230.
  16. World Health Organization. Second WHO Model List of Essential In Vitro Diagnostics. 2019; https://www.who.int/publications/i/item/WHO-MVP-EMP-2019.05.
  17. Turner D et al. Cost effectiveness of management strategies for urinary tract infections: results from randomised controlled trial. BMJ. 2010;340:c346.
  18. Alam MF et al. The additional costs of antibiotics and re-consultations for antibiotic-resistant Escherichia coli urinary tract infections managed in general practice. Int J Antimicrob Agents. 2009;33(3):255-7.
  19. Butler CC et al. Antibiotic-resistant infections in primary care are symptomatic for longer and increase workload: outcomes for patients with E. coli UTIs. Br J Gen Pract. 2006;56(530):686-92.